Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial

Phillip H. Kuo; Taylor Benson; Richard Messmann; Michael Groaning

doi:10.2967/jnumed.121.263638

EditorialEditorial

Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial

Phillip H. Kuo, Taylor Benson, Richard Messmann and Michael Groaning

Journal of Nuclear Medicine June 2022, 63 (6) 816-818; DOI: https://doi.org/10.2967/jnumed.121.263638

Phillip H. Kuo

1Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, Tucson, Arizona;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Taylor Benson

2Novartis Pharmaceuticals Corporation, Basel, Switzerland; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Richard Messmann

2Novartis Pharmaceuticals Corporation, Basel, Switzerland; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Groaning

3Amgen, Thousand Oaks, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Information

vol. 63 no. 6 816-818

DOI

https://doi.org/10.2967/jnumed.121.263638

PubMed

35086895

Published By

Society of Nuclear Medicine

Print ISSN

0161-5505

Online ISSN

2159-662X

History

Received for publication December 7, 2021
Revision received January 20, 2022
Published online June 1, 2022.

Article Versions

previous version (January 27, 2022 - 13:16).
You are viewing the most recent version of this article.

Author Information

Statistics from Altmetric.com

Cited By...

16 Citations
18 Citations
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Robert Seifert, Louise Emmett, Steven P. Rowe, Ken Herrmann, Boris Hadaschik, Jeremie Calais, Frederik L. Giesel, Robert Reiter, Tobias Maurer, Matthias Heck, Andrei Gafita, Michael J. Morris, Stefano Fanti, Wolfgang A. Weber, Thomas A. Hope, Michael S. Hofman, Wolfgang Peter Fendler, Matthias Eiber

European Urology 2023 83 5
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Clemens Kratochwil, Wolfgang P. Fendler, Matthias Eiber, Michael S. Hofman, Louise Emmett, Jeremie Calais, Joseph R. Osborne, Amir Iravani, Phillip Koo, Liza Lindenberg, Richard P. Baum, Murat Fani Bozkurt, Roberto C. Delgado Bolton, Samer Ezziddin, Flavio Forrer, Rodney J. Hicks, Thomas A. Hope, Levent Kabasakal, Mark Konijnenberg, Klaus Kopka, Michael Lassmann, Felix M. Mottaghy, Wim J. G. Oyen, Kambiz Rahbar, Heiko Schoder, Irene Virgolini, Lisa Bodei, Stefano Fanti, Uwe Haberkorn, Ken Hermann

European Journal of Nuclear Medicine and Molecular Imaging 2023 50 9
Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis

Esmée C. A. van der Sar, Adinda J. S. Kühr, Sander C. Ebbers, Andrew M. Henderson, Bart de Keizer, Marnix G. E. H. Lam, Arthur J. A. T. Braat

Biomedicines 2022 10 7
Is18F-FDG PET Needed to Assess177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis

Robert Seifert, Tugce Telli, Boris Hadaschik, Wolfgang P. Fendler, Phillip H. Kuo, Ken Herrmann

Journal of Nuclear Medicine 2023 64 5
Eligibility for177Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of68Ga-PSMA-11 and99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer

Gary J.R. Cook, Wai-Lup Wong, Bal Sanghera, Stephen Mangar, Amarnath Challapalli, Amit Bahl, Paul Bassett, Darren Leaning, Christian Schmidkonz

Journal of Nuclear Medicine 2023 64 2
Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial

Shay Golan, Michael Frumer, Yarden Zohar, Eli Rosenbaum, Maxim Yakimov, Daniel Kedar, David Margel, Jack Baniel, Adam P. Steinmetz, David Groshar, Liran Domachevsky, Hanna Bernstine

European Urology Oncology 2023 6 2
PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study

Masatoshi Hotta, Andrei Gafita, Vishnu Murthy, Matthias R. Benz, Ida Sonni, Irene A. Burger, Matthias Eiber, Louise Emmett, Andrea Farolfi, Wolfgang P. Fendler, Manuel M. Weber, Michael S. Hofman, Thomas A. Hope, Clemens Kratochwil, Johannes Czernin, Jeremie Calais

Journal of Nuclear Medicine 2023 64 7
A VISION Substudy of Reader Agreement on68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for177Lu-PSMA-617 Radioligand Therapy

Phillip H. Kuo, Don C. Yoo, Ryan Avery, Marc Seltzer, Jeremie Calais, James Nagarajah, Wolfgang A. Weber, Wolfgang P. Fendler, Michael S. Hofman, Bernd J. Krause, Marcia Brackman, Euloge Kpamegan, Samson Ghebremariam, Taylor Benson, Ana M. Catafau, Ayse T. Kendi

Journal of Nuclear Medicine 2023 64 8
Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions

Daniel Groener, Sina Schneider, Justus Baumgarten, Christian Happel, Konrad Klimek, Nicolai Mader, Christina Nguyen Ngoc, Jennifer Wichert, Philipp Mandel, Nikolaos Tselis, Frank Grünwald, Amir Sabet

Cancers 2023 15 2
RadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France

Marie Terroir, Chloé Lamesa, Mehdi Krim, Lavinia Vija, Jean-Sébastien Texier, Thibaut Cassou-Mounat, Jean-Pierre Delord, Delphine Vallot, Frédéric Courbon

Pharmaceuticals 2023 16 5

Article usage

Article usage: January 2022 to August 2023

	Full	Pdf
Jan 2022	0	178
Feb 2022	0	213
Mar 2022	0	123
Apr 2022	0	61
May 2022	0	86
Jun 2022	784	260
Jul 2022	400	100
Aug 2022	223	63
Sep 2022	382	84
Oct 2022	234	79
Nov 2022	96	67
Dec 2022	385	56
Jan 2023	411	60
Feb 2023	383	64
Mar 2023	424	73
Apr 2023	330	83
May 2023	275	65
Jun 2023	328	77
Jul 2023	380	93
Aug 2023	490	95

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 63, Issue 6

June 1, 2022

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial

Phillip H. Kuo, Taylor Benson, Richard Messmann, Michael Groaning

Journal of Nuclear Medicine Jun 2022, 63 (6) 816-818; DOI: 10.2967/jnumed.121.263638

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial

Phillip H. Kuo, Taylor Benson, Richard Messmann, Michael Groaning

Journal of Nuclear Medicine Jun 2022, 63 (6) 816-818; DOI: 10.2967/jnumed.121.263638

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Main menu

User menu

Search

Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial

Article Information

Article Versions

Author Information

Statistics from Altmetric.com

Cited By...

Article usage

Article usage: January 2022 to August 2023

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles